PD-L1 CPS utilisé comme seuil d'admissibilité pour l'ICI dans le cancer de l'oesophage métastatique....
Vue déterministe de l'entité source de la LJAM. L'autorité clinique demeure avec les ID de la source cités et l'état d'approbation de l ́examinateur.
| ID | BMA-PDL1-CPS-ESOPHAGEAL |
|---|---|
| Type | Pertinence thérapeutique |
| État | reviewed 2026-05-07 | actionability review required |
| Maladies | DIS-ESOPHAGEAL |
| Sources | SRC-ESMO-ESOPHAGEAL-2024 SRC-NCCN-ESOPHAGEAL-2025 |
Faits relatifs à l ' action en justice
| Biomarqueur | BIO-PDL1-CPS |
|---|---|
| Maladie | DIS-ESOPHAGEAL |
| Niveau ESCAT | IA |
| Combinaisons recommandées | pembrolizumab + cisplatin + fluoropyrimidine (CPS≥10 SCC 1L per SRC-NCCN-ESOPHAGEAL-2025), pembrolizumab monotherapy (CPS≥10 SCC/adeno 2L per SRC-NCCN-ESOPHAGEAL-2025) |
| Résumé des faits | PD-L1 CPS used as eligibility threshold for ICI in metastatic esophageal cancer. Esophageal SCC: CPS ≥10 — pembrolizumab + cisplatin + fluoropyrimidine 1L (KEYNOTE-590), and pembrolizumab monotherapy 2L (KEYNOTE-181 CPS≥10 subgroup). Esophageal adeno and GEJ: same CPS criteria as gastric adeno (NCCN 2025 treats GEJ adeno with gastric algorithm). Testing by IHC 22C3 pharmDx mandatory. Threshold-gated indication selection is performed by the algorithm layer (IND-ESOPH-METASTATIC-2L-PEMBRO-CPS10); this BMA entry surfaces ESCAT tier context only. |
Notes
Variant_qualifier null — threshold gating (CPS≥10) enforced by indication layer. KEYNOTE-590 and KEYNOTE-181 source stubs not yet ingested; citing NCCN/ESMO as proxies until trial source backfill PRs add them.
Utilisé par
No reverse references found in the YAML corpus.